
The FDA’s new CBER Safety Council separates post-market biologics safety review from approvals, raising oversight for cell and gene therapy developers.
Catalent Biologics is a global leader in biopharmaceutical development services, bringing next-generation therapies to the market.
Catalent Biologics is a global leader in biopharmaceutical development services, bringing next-generation therapies to the market. Its recent acquisitions of Paragon Bioservices and MaSTherCell have expanded its service portfolio to include development and manufacturing of cell and gene therapies, alongside new biological entities, biosimilars, sterile injectables, and antibody-drug conjugates.
Catalent Pharma Solutions
14 Schoolhouse Road Somerset, NJ 08873, USA
solutions@ catalent.com
tel. +1.888.765.8846





